Biotech

All Articles

Amgen records 1st phase 3 win for $400M chronic eczema medication

.Amgen has discussed (PDF) the 1st stage 3 data on its $400 thousand eczema medication, linking the ...

Biogen, UCB file phase 3 lupus gain after neglecting earlier test

.Biogen and UCB's depend improving in to phase 3 on the back of a broken research study seeks to hav...

Aptadir wishes brand-new RNA preventions can turn around complicated cancers cells

.Italian biotech Aptadir Rehabs has launched along with the commitment that its own pipeline of prec...

Wave surfs DMD results to regulatory authorities' doors, sending stock up

.Wave Life Sciences has actually satisfied its target in a Duchenne muscular dystrophy (DMD) study, ...

Sanofi tweezes new CSO from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is actually going back to the pharma layer, occu...

Achilles trickles cell therapy course, bandages for discharges after missing out on 'business stability' goals

.Achilles Rehabs has shreded its own strategy. The British biotech is knocking off on its clinical-p...

Aligos heralds phase 2 MASH gain, reducing liver body fat up to 46%

.Aligos Therapeutics is actually heralding a midstage win in metabolic-dysfunction associated steato...

Basilea credit ratings $268M BARDA financing for antifungals, prescription antibiotics

.Basilea Pharmaceutica's work developing new antifungals has gotten a significant improvement coming...

Capricor markets Europe rights to late-stage DMD treatment for $35M

.Having actually scooped up the united state legal rights to Capricor Rehabs' late-stage Duchenne mu...

FDA fragments adcomm for Applied's unusual ailment medication

.After pushing back the decision meeting for Applied Rehabs' metabolic condition drug govorestat, th...